Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

260
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
260
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

133
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
133
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

390
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
390

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Supervised Machine Learning to Identify Hospital Inpatients Needing a Change of Antibiotic Therapy in Real Time: Preclinical Diagnostic Evaluation and Feasibility Study.

Open forum infectious diseases·2026
Same author

Household carbon monoxide (CO) concentrations in a large African city: An unquantified public health burden?

Environmental pollution (Barking, Essex : 1987)·2024
Same author

An example of governance for AI in health services from Aotearoa New Zealand.

NPJ digital medicine·2023
Same author

The usability of daytime and night-time heart rate dynamics as digital biomarkers of depression severity.

Psychological medicine·2023
Same author

Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis.

Multiple sclerosis and related disorders·2022
Same author

Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis.

Multiple sclerosis and related disorders·2021
Same journal

Bridging to low-dose corticosteroids after satralizumab discontinuation in unplanned pregnancy: Two cases of AQP4-positive NMOSD.

Multiple sclerosis and related disorders·2026
Same journal

Does laughter yoga really improve fatigue, sleep quality and psychological wellbeing in people living with MS?

Multiple sclerosis and related disorders·2026
Same journal

The many faces of the multiple sclerosis population in Canada.

Multiple sclerosis and related disorders·2026
Same journal

Patterns of psychological resilience and social avoidance among the patients of Neuromyelitis Optica Spectrum Disease: a latent profile analysis.

Multiple sclerosis and related disorders·2026
Same journal

Discontinuation of disease-modifying therapies in patients with multiple sclerosis: A retrospective case-control study.

Multiple sclerosis and related disorders·2026
Same journal

Real-world analytical and clinical evaluation of the Siemens Atellica® immunoassay for plasma neurofilament light chain in multiple sclerosis.

Multiple sclerosis and related disorders·2026
See all related articles

Related Experiment Video

Updated: Apr 14, 2026

Recording Network Activity in Spinal Nociceptive Circuits Using Microelectrode Arrays
11:28

Recording Network Activity in Spinal Nociceptive Circuits Using Microelectrode Arrays

Published on: February 9, 2022

3.5K

Sustained-release fampridine in Multiple Sclerosis.

S Hadavi1, M D Baker1, R Dobson1

  • 1Blizard Institute, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, London, UK.

Multiple Sclerosis and Related Disorders
|April 17, 2015
PubMed
Summary
This summary is machine-generated.

Sustained-release fampridine offers a potential treatment for walking difficulties in multiple sclerosis (MS), with about one-third of patients showing improvement. While approved elsewhere, UK access is limited by barriers, despite its acceptable safety profile at lower doses.

Keywords:
Clinical trialsDisabilityFampridineMultiple SclerosisSafetyWalking

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K
Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry CIS-FSCV to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine
06:40

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry CIS-FSCV to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine

Published on: April 23, 2020

3.8K

Related Experiment Videos

Last Updated: Apr 14, 2026

Recording Network Activity in Spinal Nociceptive Circuits Using Microelectrode Arrays
11:28

Recording Network Activity in Spinal Nociceptive Circuits Using Microelectrode Arrays

Published on: February 9, 2022

3.5K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K
Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry CIS-FSCV to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine
06:40

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry CIS-FSCV to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine

Published on: April 23, 2020

3.8K

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Medicine

Background:

  • Multiple Sclerosis (MS) is a chronic neurological disease impacting mobility.
  • Walking difficulties are a common and significant symptom in MS patients.
  • Current symptomatic treatments for MS-related walking impairment are limited.

Purpose of the Study:

  • To evaluate the efficacy and safety of sustained-release fampridine for improving walking in multiple sclerosis.
  • To discuss the current regulatory status and clinical accessibility of fampridine in the UK.
  • To address concerns regarding seizure risk associated with fampridine treatment.

Main Methods:

  • Review of clinical studies demonstrating fampridine's effect on walking speed in MS patients.
  • Analysis of adverse event data from open-label extension studies.
  • Examination of regulatory approvals (FDA, EMA) and National Health Service (NHS) availability.

Main Results:

  • Approximately one-third of MS patients experience a clear benefit in walking speed with sustained-release fampridine.
  • Fampridine demonstrates an acceptable adverse event profile, particularly at lower doses.
  • Higher doses of fampridine were associated with an increased rate of seizures, but this was not significant at lower doses.

Conclusions:

  • Sustained-release fampridine is a promising symptomatic treatment for improving walking in MS.
  • Despite regulatory approvals in the US and Europe, significant barriers limit its use in the UK.
  • Further investigation and potential policy changes are needed to facilitate wider clinical adoption for MS patients.